M&A Deal Summary |
|
|---|---|
| Date | 2008-05-21 |
| Target | U3 Pharma AG |
| Sector | Life Science |
| Buyer(s) | Daiichi Sankyo |
| Sellers(s) | Alta Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 234M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1899 |
| Sector | Life Science |
| Employees | 19,765 |
| Revenue | 1.89T JPY (2025) |
Daiichi Sankyo manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals. Daiichi Sankyo was founded in 1899 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 4 |
| Sector: Life Science M&A | 1 of 4 |
| Type: Add-on Acquisition M&A Deals | 1 of 4 |
| Country: Germany M&A | 1 of 1 |
| Year: 2008 M&A | 1 of 2 |
| Size (of disclosed) | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-06-11 |
Ranbaxy Laboratories
New Delhi, India Ranbaxy Limited is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed and emerging 4 markets, many of which incorporate proprietary Novel Drug Delivery Systems and technologies developed at its own labs. |
Buy | $5.5B |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 2.6B USD |
| Size | Large |
| Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 38 of 85 |
| Sector: Life Science M&A | 25 of 65 |
| Type: Add-on Acquisition M&A Deals | 25 of 45 |
| Country: Germany M&A | 1 of 1 |
| Year: 2008 M&A | 1 of 4 |
| Size (of disclosed) | 15 of 23 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-03-05 |
Trevena
Chesterbrook, Pennsylvania, United States Trevena is a biopharmaceutical company dedicated to delivering groundbreaking medicines to address the critical needs of patients with central nervous system (CNS) disorders. Trevena was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-05-29 |
Kosan Biosciences
Hayward, California, United States Kosan Biosciences is an established cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. |
Sell | - |
